Regeneron (REGN) Stock Forecast & Price Target

Compare

4,662 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Moderate Buy

17 Buy

5 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$724.35

▲(49.95%Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $724.35 with a high forecast of $900.00 and a low forecast of $535.00. The average price target represents a 49.95% change from the last price of $483.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"489":"$489","1182":"$1,182","662.25":"$662.3","835.5":"$835.5","1008.75":"$1,008.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$900.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":724.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$724.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":535,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$535.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[489,662.25,835.5,1008.75,1182],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,490.81,522.2861538461539,553.7623076923077,585.2384615384615,616.7146153846154,648.1907692307692,679.666923076923,711.1430769230769,742.6192307692307,774.0953846153845,805.5715384615385,837.0476923076924,868.5238461538461,{"y":900,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,490.81,508.7746153846154,526.7392307692307,544.7038461538461,562.6684615384615,580.6330769230769,598.5976923076923,616.5623076923077,634.5269230769231,652.4915384615385,670.4561538461538,688.4207692307692,706.3853846153846,{"y":724.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,490.81,494.20923076923077,497.60846153846154,501.0076923076923,504.4069230769231,507.80615384615385,511.2053846153846,514.6046153846154,518.0038461538461,521.4030769230769,524.8023076923077,528.2015384615385,531.6007692307692,{"y":535,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":977.46,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1054.11,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1090.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1181.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1044.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":841.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":760.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":710.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":671.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":697.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":616.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":589.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":490.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$900.00

Average Price Target$724.35

Lowest Price Target$535.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$532

Hold

10.13%

Upside

Downgraded

05/31/25

Regeneron's overall stock score reflects strong financial performance and a reasonable valuation. However, bearish technical indicators and mixed earnings call results highlight challenges and uncertainties, balancing the positive financial aspects.

Trung HuynhUBS

UBS

$633→$560

Hold

15.93%

Upside

Reiterated

06/05/25

UBS Remains a Hold on Regeneron (REGN)

Akash TewariJefferies

Jefferies

$914→$804

Buy

66.44%

Upside

Reiterated

06/04/25

Regeneron: Buy Rating Backed by Promising Pipeline and Market Expansion Potential

Brian AbrahamsRBC Capital

RBC Capital

$662

Hold

37.04%

Upside

Reiterated

06/03/25

RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN)

Cory KasimovEvercore ISI

Evercore ISI

$900

Buy

86.31%

Upside

Reiterated

06/02/25

Evercore ISI Sticks to Its Buy Rating for Regeneron (REGN)

David RisingerLeerink Partners

Leerink Partners

$686→$645

Buy

33.52%

Upside

Reiterated

06/02/25

Regeneron: Buy Rating Reaffirmed Amid Growth Prospects and Attractive Valuation

Evan SeigermanBMO Capital

BMO Capital

$800→$600

Buy

24.21%

Upside

Reiterated

06/02/25

Regeneron price target lowered to $600 from $800 at BMO CapitalRegeneron price target lowered to $600 from $800 at BMO Capital

Terence FlynnMorgan Stanley

Morgan Stanley

$958→$755

Buy

56.29%

Upside

Reiterated

06/02/25

Regeneron (REGN) Gets a Buy from Morgan Stanley

Geoff MeachamCiti

Citi

$700→$650

Buy

34.56%

Upside

Reiterated

06/02/25

Buy Rating Maintained for Regeneron Despite Mixed Trial Results, Driven by Promising Pipeline and Growth Prospects

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/02/25

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

William PickeringBernstein

Bernstein

$896→$750

Buy

55.26%

Upside

Reiterated

06/02/25

Bernstein Sticks to Its Buy Rating for Regeneron (REGN)

John NewmanCanaccord Genuity

Canaccord Genuity

$850

Buy

75.96%

Upside

Reiterated

06/02/25

Optimistic Outlook on Regeneron Despite Mixed AERIFY Trial Results

Tyler Van BurenTD Cowen

TD Cowen

$800

Buy

65.61%

Upside

Reiterated

06/02/25

TD Cowen Keeps Their Buy Rating on Regeneron (REGN)

Tim AndersonBank of America Securities

Bank of America Securities

$535

Sell

10.75%

Upside

Reiterated

05/30/25

Cautious Outlook on Regeneron: Mixed Itepekimab Results and Eylea Challenges Drive Sell Rating

Yatin SunejaGuggenheim

Guggenheim

$810

Buy

67.68%

Upside

Reiterated

05/30/25

Regeneron (REGN) Gets a Buy from Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$532

Hold

10.13%

Upside

Downgraded

05/31/25

Trung HuynhUBS

UBS

$633→$560

Hold

15.93%

Upside

Reiterated

06/05/25

UBS Remains a Hold on Regeneron (REGN)

Akash TewariJefferies

Jefferies

$914→$804

Buy

66.44%

Upside

Reiterated

06/04/25

Regeneron: Buy Rating Backed by Promising Pipeline and Market Expansion Potential

Brian AbrahamsRBC Capital

RBC Capital

$662

Hold

37.04%

Upside

Reiterated

06/03/25

RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN)

Cory KasimovEvercore ISI

Evercore ISI

$900

Buy

86.31%

Upside

Reiterated

06/02/25

Evercore ISI Sticks to Its Buy Rating for Regeneron (REGN)

David RisingerLeerink Partners

Leerink Partners

$686→$645

Buy

33.52%

Upside

Reiterated

06/02/25

Regeneron: Buy Rating Reaffirmed Amid Growth Prospects and Attractive Valuation

Evan SeigermanBMO Capital

BMO Capital

$800→$600

Buy

24.21%

Upside

Reiterated

06/02/25

Regeneron price target lowered to $600 from $800 at BMO CapitalRegeneron price target lowered to $600 from $800 at BMO Capital

Terence FlynnMorgan Stanley

Morgan Stanley

$958→$755

Buy

56.29%

Upside

Reiterated

06/02/25

Regeneron (REGN) Gets a Buy from Morgan Stanley

Geoff MeachamCiti

Citi

$700→$650

Buy

34.56%

Upside

Reiterated

06/02/25

Buy Rating Maintained for Regeneron Despite Mixed Trial Results, Driven by Promising Pipeline and Growth Prospects

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/02/25

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

William PickeringBernstein

Bernstein

$896→$750

Buy

55.26%

Upside

Reiterated

06/02/25

Bernstein Sticks to Its Buy Rating for Regeneron (REGN)

John NewmanCanaccord Genuity

Canaccord Genuity

$850

Buy

75.96%

Upside

Reiterated

06/02/25

Optimistic Outlook on Regeneron Despite Mixed AERIFY Trial Results

Tyler Van BurenTD Cowen

TD Cowen

$800

Buy

65.61%

Upside

Reiterated

06/02/25

TD Cowen Keeps Their Buy Rating on Regeneron (REGN)

Tim AndersonBank of America Securities

Bank of America Securities

$535

Sell

10.75%

Upside

Reiterated

05/30/25

Cautious Outlook on Regeneron: Mixed Itepekimab Results and Eylea Challenges Drive Sell Rating

Yatin SunejaGuggenheim

Guggenheim

$810

Buy

67.68%

Upside

Reiterated

05/30/25

Regeneron (REGN) Gets a Buy from Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month

xxx

Success Rate

23/36 ratings generated profit

Average Return

+3.44%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.89% of your transactions generating a profit, with an average return of +3.44% per trade.

3 Months

xxx

Success Rate

23/36 ratings generated profit

Average Return

+8.21%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.89% of your transactions generating a profit, with an average return of +8.21% per trade.

1 Year

Christopher RaymondPiper Sandler

Success Rate

27/41 ratings generated profit

Average Return

+9.11%

assigned a buy rating 4 months ago

Copying Christopher Raymond's trades and holding each position for 1 Year would result in 65.85% of your transactions generating a profit, with an average return of +9.11% per trade.

2 Years

xxx

Success Rate

29/36 ratings generated profit

Average Return

+36.56%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.56% of your transactions generating a profit, with an average return of +36.56% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 55 Buy Ratings, 10 Hold Ratings, and 5 Sell Ratings. REGN average Analyst price target in the past 3 months is 724.35.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $8.53 with a range of $4.25 to $10.25. The previous quarter’s EPS was $8.22. REGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year REGN has Outperformed its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.29B with a range of $3.10B to $3.51B. The previous quarter’s sales results were $3.03B. REGN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year REGN has Outperformed its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 724.35.

What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron Pharmaceuticals has 49.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron Pharmaceuticals has a consensus rating of Moderate Buy which is based on 17 buy ratings, 5 hold ratings and 1 sell ratings.

What is Regeneron Pharmaceuticals’s price target?

The average price target for Regeneron Pharmaceuticals is 724.35. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $900.00 ,the lowest forecast is $535.00. The average price target represents 49.95% Increase from the current price of $483.07.

What do analysts say about Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts